

Riikka Karjalainen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11101433/publications.pdf>

Version: 2024-02-01

15
papers

756
citations

1307594

7
h-index

1372567

10
g-index

16
all docs

16
docs citations

16
times ranked

1657
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1416-1429. | 9.4 | 334 |
| 2 | Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. <i>Scientific Reports</i> , 2014, 4, 5193. | 3.3 | 243 |
| 3 | JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. <i>Blood</i> , 2017, 130, 789-802. | 1.4 | 90 |
| 4 | Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. <i>Oncotarget</i> , 2017, 8, 56338-56350. | 1.8 | 35 |
| 5 | Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. <i>Leukemia</i> , 2019, 33, 2548-2553. | 7.2 | 25 |
| 6 | Targeting of JAK/STAT Signaling to Reverse Stroma-Induced Cytoprotection Against BCL2 Antagonist Venetoclax in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 32-32. | 1.4 | 14 |
| 7 | Statistical detection of quantitative protein biomarkers provides insights into signaling networks deregulated in acute myeloid leukemia. <i>Proteomics</i> , 2014, 14, 2443-2453. | 2.2 | 10 |
| 8 | Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. <i>Blood</i> , 2014, 124, 2046-2046. | 1.4 | 3 |
| 9 | Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. <i>Blood</i> , 2017, 130, 854-854. | 1.4 | 1 |
| 10 | High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. <i>Blood</i> , 2012, 120, 288-288. | 1.4 | 1 |
| 11 | Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. <i>Blood</i> , 2011, 118, 2487-2487. | 1.4 | 0 |
| 12 | Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies. <i>Blood</i> , 2013, 122, 1668-1668. | 1.4 | 0 |
| 13 | Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. <i>Blood</i> , 2013, 122, 482-482. | 1.4 | 0 |
| 14 | Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing. <i>Blood</i> , 2014, 124, 3505-3505. | 1.4 | 0 |
| 15 | Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma. <i>Blood</i> , 2014, 124, 646-646. | 1.4 | 0 |